严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株KP.1.1、LB.1和KP3.3对已获批单克隆抗体产生逃逸

Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP3.3 From Approved Monoclonal Antibodies.

作者信息

Planas Delphine, Staropoli Isabelle, Planchais Cyril, Yab Emilie, Jeyarajah Banujaa, Rahou Yannis, Prot Matthieu, Guivel-Benhassine Florence, Lemoine Frederic, Enouf Vincent, Simon-Loriere Etienne, Mouquet Hugo, Rameix-Welti Marie-Anne, Schwartz Olivier

机构信息

Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.

Vaccine Research Institute, Créteil, France.

出版信息

Pathog Immun. 2024 Sep 30;10(1):1-11. doi: 10.20411/pai.v10i1.752. eCollection 2024.

DOI:10.20411/pai.v10i1.752

PMID:39391808

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11464000/

Abstract

BACKGROUND

First-generation anti-SARS-CoV-2 monoclonal antibodies (mAbs) used for prophylaxis or therapeutic purposes in immunocompromised patients have been withdrawn because of the emergence of resistant Omicron variants. In 2024, 2 novel mAbs, VYD222/Pemivibart and AZD3152/Sipavibart, were approved by health authorities, but their activity against contemporary JN.1 sublineages is poorly characterized.

METHODS

We isolated authentic JN.1.1, KP.1.1, LB.1, and KP.3.3 viruses and evaluated their sensitivity to neutralization by these mAbs in 2 target cell lines.

RESULTS

Compared to ancestral strains, VYD222/Pemivibart remained moderately active against JN.1 subvariants, with a strong increase of 50% Inhibitory Concentration (IC50), reaching up to 3 to 15 µg/mL for KP3.3. AZD3152/Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP.1.1, LB.1, and KP3.3.

CONCLUSIONS

Our results highlight the need for a close clinical monitoring of VYD222/Pemivibart and raise concerns about the clinical efficacy of AZD3152/Sipavibart.

摘要